Sareum Regulatory News (SAR)

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Pre-Close Trading Statement

Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, provides the following trading update ahead of its full year results for the year ending 30 June 2017.

The Company is pleased to report that subject to audit, it now expects that the profit for the year after tax and cash at bank, for its results for the year ended 30 June 2017, to be ahead of market expectations.

An update on progress with its cancer and autoimmune disease research and development programmes will be given in mid-late October 2017 when the Company expects to report its full year results.

For further information, please contact: 

Notes for editors: 

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and licensing them to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with international collaborators and a world-wide network of research providers. Its most advanced programme (Chk1) commenced clinical trials in May 2016 and was licensed to NASDAQ-listed Sierra Oncology in September 2016.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease research programmes, which are in the IND-enabling preclinical and lead optimisation stages respectively. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

- Ends -